Publications

• A Dual-Lumen Percutaneous Cannula for Managing Refractory Right Ventricular Failure.

  (Badu B, Cain MT, Durham LA 3rd, Joyce LD, Sundararajan S, Gaglianello N, Ishizawar D, Saltzberg M, Mohammed A, Joyce DL.) ASAIO J. 2020 08;66(8):915-921 PMID: 32740352 SCOPUS ID: 2-s2.0-85088908095 08/03/2020

• Association of preoperative duration of inotropy on prevalence of right ventricular failure following LVAD implantation.

  (Benjamin MM, Sundararajan S, Sulaiman S, Miles B, Walker RJ, Durham L, Kohmoto T, Joyce DL, Ishizawar D, Gaglianello N, Mohammed A.) ESC Heart Fail. 2020 08;7(4):1949-1955 PMID: 32526807 PMCID: PMC7373884 SCOPUS ID: 2-s2.0-85086232769 06/12/2020

• Minimally Invasive Mechanical Circulatory Support Through the Perioperative Pulmonary Thromboendarterectomy Period: A Case Report.

  (Schurman AM, Cain MT, Joyce DL, Durham LA, Ishizawar D, Mohammed A, Joyce LD.) Innovations (Phila). 2020 Mar/Apr;15(2):173-176 PMID: 32352901 SCOPUS ID: 2-s2.0-85084170601 05/01/2020

• Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension.

  (Coons JC, Bunner C, Ishizawar DC, Risbano MG, Rivera-Lebron B, Mathier MA, Chan SY, Simon MA.) Pulm Circ. 2018 Jan-Mar;8(1):2045893217744512 PMID: 29199910 PMCID: PMC5731722 12/05/2017

• Oral treprostinil for the treatment of pulmonary arterial hypertension in patients transitioned from parenteral or inhaled prostacyclins: case series and treatment protocol.

  (Coons JC, Miller T, Simon MA, Ishizawar DC, Mathier MA.) Pulm Circ. 2016 Mar;6(1):132-5 PMID: 27162621 PMCID: PMC4860543 05/11/2016

• Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension.

  (Preston IR, Feldman J, White J, Franco V, Ishizawar D, Burger C, Waxman AB, Hill NS.) Pulm Circ. 2014 Sep;4(3):456-61 PMID: 25621159 PMCID: PMC4278605 01/27/2015

• High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4.

  (Bauer EM, Shapiro R, Zheng H, Ahmad F, Ishizawar D, Comhair SA, Erzurum SC, Billiar TR, Bauer PM.) Mol Med. 2013 Feb 08;18:1509-18 PMID: 23269975 PMCID: PMC3576475 12/28/2012

• Bosentan.

  (Mathier MA, Ishizawar D.) Expert Opin Pharmacother. 2010 Apr;11(6):1023-34 PMID: 20307226 03/24/2010

• Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.

  (Rajkumar R, Konishi K, Richards TJ, Ishizawar DC, Wiechert AC, Kaminski N, Ahmad F.) Am J Physiol Heart Circ Physiol. 2010 Apr;298(4):H1235-48 PMID: 20081107 PMCID: PMC2853417 01/19/2010

• Racial differences in heart failure therapeutics.

  (Ishizawar D, Yancy C.) Heart Fail Clin. 2010 Jan;6(1):65-74 PMID: 19945062 12/01/2009

• The beta1-adrenergic receptor mediates the pharmacogenetic interaction of the ACE D allele and beta-blockers.

  (Ishizawar DC, Janosko KM, Teuteberg JJ, Cadaret LM, Mathier MA, McNamara DM.) Clin Transl Sci. 2008 Sep;1(2):151-4 PMID: 20443839 PMCID: PMC5439562 09/01/2008